FDA heavily criticized by independent institute over Biogen approval

Independent US research institute ICER has criticized the FDA over its recent approval, saying it believes more studies are required to alleviate "substantial" uncertainty surrounding Biogen's drug, Aduhelm.

The US Food and Drug Administration (FDA) approved Biogen's Alzheimer's drug Aduhelm on Monday, and that decision is now being criticized.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs